Advances in Vision Research, Volume III

Dr. Gyan Prakash is Director of Office of International Program Activities at National Eye Institute (NEI)- National Institutes of Health (NIH), USA. He served as the first Director of Transformational Medical Technologies Initiative (TMTI), a pioneer scientific research and product development program in the US Government with a budget of US$ 1.6 Billion. Before joining the U.S. Gov’t, Dr. Prakash served as the Chief Operating Officer and Executive Vice President at AMAR International, a life science program management company in the USA. Previously, he served as the President and CEO of Metastatin Pharmaceuticals. Dr. Prakash earned his international program management experience at Pfizer world headquarters in New York in several leadership roles. He has a PhD in Biomedical Sciences earned at University of Illinois at Urbana-Champaign and MBA in Management and fellowships at UCLA School of Medicine and Centers for Disease Control. He is the founding President of Global Eye Genetics Consortium (GEGC), previously Asian Eye Genetics Consortium (AEGC). Dr. Takeshi Iwata is Director of Molecular and Cellular Biology Division at National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center in Tokyo, Japan. He is known for his pioneering work in the field of retinal genetics and has worked at National Institutes of Health (NIH)- National Eye Institute (NEI) in Bethesda, MD, USA, in retina genetics laboratory, headed by Dr. George Inana. He and Dr. Inana moved to Bascom Palmer Eye Institute, University of Miami School of Medicine in Miami, Florida and continued working on inherited retinal diseases. Dr. Iwata returned to NEI laboratory headed by Dr. Deborah Carper on another major retinal disease, the diabetic retinopathy. Dr. Iwata earned his PhD at Meijo University in Japan. He is currently serving as President of Japan Eye Genetics Consortium (JEGC) and Global Eye Genetics Consortium (GEGC).

• 1. Expansion of Asian Eye Genetics Consortium (AEGC) to Global Eye Genetics Consortium (GEGC), Introduction of a global Phenotype-Genotype Database “GenEye” and Launch of New Training Programs at National Eye Institute (NEI).- 2. Global Women’s Eye Health: a Genetic Epidemiologic perspective.- 3. Establishing the Chinese Arm of GEGC.- 4. Human material for research: Eye banking, biobanking and ethical access.- 5. Current Understanding of Polypoidal Choroidal Vasculopathy.- 6. Genetics of Age-related macular degeneration (AMD) in Asia.- 7. The contribution of rare allele and Junk Genome in AMD pathogenesis.- 8. Differential genotypes in age-related macular degeneration and polypoidal choroidal vasculopathy: a updated meta-analysis.- 9. Genetic Epidemiology of Quantitative Traits of Primary Open Angle Glaucoma.- 10. Association studies on retina diseases in Chinese population.- 11. Congenital stationary night blindness (CSNB) – an inherited retinal disorder where clear correlations can be made.- 12. Genome analysis for inherited retinal disease: the state of the art.- 13. Generation and analysis of induced photoreceptor-like cells from fibroblasts of patients with retinitis pigmentosa.- 14. Genotype-phenotype of RPE65 mutations: A reference guide for gene testing and its clinical application.- 15. Genetic variants and impact in PDE6B rod-cone dystrophy.- 16. The retinitis pigmentosa genes.- 17. Primary Congenital Glaucoma Genetics – The Experience in Brazil.- 18. Glaucoma genetics in Pakistan.- 19. Contributions of Promoter Variants to Complex Eye Diseases.- 20. Vascular Basement Membrane Thickening – Basis of disease pathology in diabetic retinopathy.- 21. Molecular Genetics and Clinical aspects of Macular Corneal Dystrophy.- 22. Congenital and Inherited Cataracts.- 23. Higher order aberrations:  differences among populations from various demographics.- 24. Genetics Of Microphthalmia: Global And Indian Perspectives.- 25. Regional Differences in Prevalence of Myopia: Genetic or Environmental Effects?.- 26. Consortium for Refractive Error and Myopia (CREAM): Vision, Mission and Accomplishments.- 27. Oncologic properties of retinoblastoma genes.- 28. Oncologic implications of genetic and epigenetic basis of pterygium.- 29. The need for alternative therapies in eye disorders.- 30. Gene Therapy and Retinal Disease.- 31. The use of human pluripotent stem cells (hPSCs) and CRISPR-mediated gene editing in retinal diseases.